Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the first‐line management of NSCLC patients with activating mutations within the kinase domain of the EGFR gene. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.